Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Merck ends the sorry saga of BTK inhibitor it got from ArQule

Merck has ended development of a BTK inhibitor that was the main reason it bought ArQule for $2.7 billion in 2019. Nemtabrutinib, aka MK-1026, was being investigated in a slew of trials in blood cancers ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 18 November →